Use of Folin-Ciocalteu phenol reagent and 3-methyl-2-benzothiazolinone hydrazine hydrochloride in the determination of oxcarbazepine in pharmaceuticals

Open access

Use of Folin-Ciocalteu phenol reagent and 3-methyl-2-benzothiazolinone hydrazine hydrochloride in the determination of oxcarbazepine in pharmaceuticals

Two spectrophotometric methods are proposed for the assay of oxcarbazepine (OXC) in bulk and dosage forms using Folin-Ciocalteu phenol reagent (FCP) and 3-methyl-2-benzothiazolinone hydrazine hydrochloride (MBTH) as reagents. The first method involves addition of FCP reagent to OXC in alkaline medium followed by measurement of absorbance at 760 nm (method A), and the other involves addition of a fixed volume of MBTH after treatment of OXC with ferric chloride and measurement of absorbance at 456 nm (method B). In both methods, the amount of chromogen formed corresponds to the amount of OXC and the measured absorbance was found to increase linearly with the concentration of OXC, which is corroborated by the correlation coefficients of 0.9985 and 0.9984 for method A and B, respectively.

The systems obey Beer's law for 5--30 μg mL-1 and 10--50 μg mL-1 for methods A and B, respectively. The apparent molar absorptivity was calculated to be 8.06 x 103 L mol-1 cm-1 and 3.126 x 103 L mol-1 cm-1 for methods A and B, respectively. The limits of detection (LOD) and limit of quantification (LOQ) were calculated to be 1.6 and 5 μg mL-1 for method A and 3 and 10 μg mL-1 for method B. The inter-day and intra-day imprecision of the methods were found to be in the range of 1.1--1.7 and 0.9--1.1% for method A, and 1.1--1.9 and 0.6--0.9% for method B. The accuracy ranged between 98.9--99.7% and 99.3--100.1 for method A and B, respectively. No interference was observed from common pharmaceutical excipients. The methods were successfully applied to the assay of OXC in tablet preparations.

The Merck Index, 13th ed., Merck & Co., Inc., White house Station (NJ) 2001, p. 1240.

L. Franceschi and M. Furlanut, A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients, Pharmacol. Res.51 (2005) 297-302; DOI: 10.1016/j.phrs.2004.09.008.

M. Klys, S. Rojek and F. Bolechala, Determination of oxcarbazepine and its metabolites in postmortem blood and hair by means of liquid chromatography with mass detection (HPLC/APCI/MS), J. Chromatogr. B825 (2005) 38-46; DOI: 10.1016/j.jchromb.2005.02.004.

D. B. Pathare, A. S. Jadhav and M. S. Shingare, A validated stability indicating method for oxcarbazepine, J. Pharm. Biomed. Anal.43 (2007) 1825-1830; DOI: 10.1016/j.jpba.2006.12.002.

M. E. B. Calvo, O. D. Renedo and M. J. Martinez, Determination of oxcarbazepine by square wave adsorptive stripping voltammetry in pharmaceutical preparations, J. Pharm. Biomed. Anal.43 (2007) 1156-1160; DOI: 10.1016/j.jpba.2006.09.029.

V. Kimiskidis, M. Spanakis, I. Niopas, D. Kazis, C. Gabrieli, F. Imad Kanaze and D. Divanoglou, Development and validation of high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study, J. Pharm. Biomed. Anal.43 (2007) 763-768; DOI: 10.1016/j.jpba.2006.07.047.

K. Lanckmans, R. Clinckers, A. V. Eeckhaut, S. Sarrre, I. Smolders and Y. Michotte, Use of micro bore LC-MS/MS for the quantitation of oxcarbazepine and its active metabolite in rat brain micro dialysis samples, J. Chromatogr. B.831 (2006) 205-212; DOI: 10.1016/j.jchromb.2005.12.003.

C. S. Ramaa, P. P. Chothe, A. A. Naik and V. J. Kadam, Spectrophotometric method for the estimation of oxcarbazepine in tablets, Indian J. Pharm. Sci.68 (2006) 265-266.

M. L. Qi, P. Wang, L. J. Wang and R. N. Fu, LC method for the determination of oxcarbazepine in pharmaceutical preparations, J. Pharm. Anal.31 (2003) 57-62.

ICH Harmonized Tripartite Guideline, ICH Topic Q2B, Validation of analytical Procedures: Methodology, ICH, London 1996.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 177 177 29
PDF Downloads 30 30 7